Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than with Ibrutinib Alone or FCR Regimen Among Patients with CLL By Ogkologos - October 13, 2025 265 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FLAIR study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Do as I say, not as I do – when the... July 13, 2021 ETV6 Protein Could Be an Important Target for Ewing Sarcoma Treatment March 7, 2023 Breast Cancer Survivor Given 12 Months to Live After Left Side... April 2, 2021 The 10 Things That Helped Me Cope With My 2 Cancer... February 6, 2024 Load more HOT NEWS Triple Therapy with Pertuzumab, Trastuzumab and Docetaxel is Feasible and Tolerable... NCI Expands Repository of Cancer Research Models: A Conversation with Drs.... FDA Approves Device for Treatment of Osteoid Osteoma in the Extremities High Response Rates Observed Following KTE-X19 CAR T-Cell Therapy in Adults...
